Filtered By:
Specialty: Neurology
Condition: Stroke
Drug: Enalapril

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 5 results found since Jan 2013.

Homocysteine and Stroke Risk Clinical Sciences
Conclusions—In Chinese hypertensive patients, the effect of homocysteine on the first stroke was significantly modified by the methylenetetrahydrofolate reductase C677T genotype and folic acid supplementation. Such information may help to more precisely predict stroke risk and develop folic acid interventions tailored to individual genetic background and nutritional status.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00794885.
Source: Stroke - April 24, 2017 Category: Neurology Authors: Min Zhao, Xiaobin Wang, Mingli He, Xianhui Qin, Genfu Tang, Yong Huo, Jianping Li, Jia Fu, Xiao Huang, Xiaoshu Cheng, Binyan Wang, Fan Fan Hou, Ningling Sun, Yefeng Cai Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

Effect of Smoking and Folate Levels on the Efficacy of Folic Acid Therapy in Prevention of Stroke in Hypertensive Men Clinical Sciences
Conclusions—Baseline folate levels and smoking status can interactively affect the risk of first stroke. Our data suggest that compared with never smokers, ever smokers may require a higher dosage of folic acid to achieve a greater beneficial effect on stroke. Our findings need to be confirmed by future randomized trials.Clinical Trial Registration—URL: https://www.clinicaltrials.gov. Unique identifier: NCT00794885.
Source: Stroke - December 22, 2017 Category: Neurology Authors: Ziyi Zhou, Jianping Li, Yaren Yu, Youbao Li, Yan Zhang, Lishun Liu, Yun Song, Min Zhao, Yu Wang, Genfu Tang, Mingli He, Xiping Xu, Yefeng Cai, Qiang Dong, Delu Yin, Xiao Huang, Xiaoshu Cheng, Binyan Wang, Fan Fan Hou, Xiaobin Wang, Xianhui Qin, Yong Huo Tags: Primary Prevention, Hypertension, Treatment, Cerebrovascular Disease/Stroke Original Contributions Source Type: research

Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients Clinical Sciences
Background and Purpose—We sought to determine whether folic acid supplementation can independently reduce the risk of first stroke associated with elevated total cholesterol levels in a subanalysis using data from the CSPPT (China Stroke Primary Prevention Trial), a double-blind, randomized controlled trial.Methods—A total of 20 702 hypertensive adults without a history of major cardiovascular disease were randomly assigned to a double-blind daily treatment of an enalapril 10-mg and a folic acid 0.8-mg tablet or an enalapril 10-mg tablet alone. The primary outcome was first stroke.Results—The median treatment durat...
Source: Stroke - October 23, 2016 Category: Neurology Authors: Qin, X., Li, J., Spence, J. D., Zhang, Y., Li, Y., Wang, X., Wang, B., Sun, N., Chen, F., Guo, J., Yin, D., Sun, L., Tang, G., He, M., Fu, J., Cai, Y., Shi, X., Ye, P., Chen, H., Zhao, S., Chen, M., Gao, C., Kong, X., Hou, F. F., Huang, Y., Huo, Y. Tags: Clinical Studies, Diet and Nutrition, Primary Prevention, Hypertension, Ischemic Stroke Original Contributions Source Type: research

Joint Association of Low Vitamin K1 and D Status With First Stroke in General Hypertensive Adults: Results From the China Stroke Primary Prevention Trial (CSPPT)
ConclusionLow concentrations of both vitamin K1 and 25(OH)D were associated with increased risk of stroke.
Source: Frontiers in Neurology - May 12, 2022 Category: Neurology Source Type: research

In Context News in brief
Folic acid can reduce risk of first stroke, according to the results of a double-blind trial. 20 702 people with hypertension without a history of stroke or myocardial infarction enrolled in the China Stroke Primary Prevention Trial were randomly assigned to receive either combined enalapril 10 mg and folic acid 0·8 mg or enalapril 10 mg alone. The trial was terminated early, after a median of 4·5 years, when benefits of the combined treatment were identified: there was a significant reduction in risk of first stroke in the folic acid-enalapril group (hazard ratio 0·79, 95% CI 0·68–0·93) compared with enalapril alone group.
Source: Lancet Neurology - April 13, 2015 Category: Neurology Tags: In Context Source Type: research